STOCK TITAN

PERKINELMER INC - PKI STOCK NEWS

Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.

Overview of PerkinElmer Inc.

PerkinElmer Inc. is a globally recognized scientific instrumentation and solutions provider that serves the needs of researchers, clinicians, and scientists in diagnostics, life sciences, and applied markets. With decades of expertise, the company combines state-of-the-art technology with deep industry knowledge to deliver instruments and software that empower precise and early insights in analytical and diagnostic processes.

Core Business Areas

PerkinElmer specializes in multiple business areas, including:

  • Diagnostics: Offering advanced tools and methodologies designed to support early disease detection and accurate diagnostics.
  • Life Sciences: Providing instrumentation and support services that enhance biological research, drug discovery, and genomic studies.
  • Food and Applied Markets: Delivering practical solutions tailored to food safety, environmental monitoring, and quality control.

Business Model and Revenue Generation

The company operates by integrating advanced science and technology with customer-focused services, generating revenue through direct sales of high-performance analytical instruments, licensing of proprietary technologies, and ongoing service contracts. The business model emphasizes long-term customer partnerships and continuous innovation, which are vital in meeting the evolving needs of global research communities.

Market Position and Competitive Landscape

Positioned as a significant player in the scientific instrumentation sector, PerkinElmer competes with other global providers by offering an extensive portfolio of integrated solutions. Its competitive edge stems from its deep technical expertise, robust customer service, and strategic investments in research and development. This approach not only addresses current market challenges but also establishes a broad framework that supports complex research endeavors and regulatory needs.

Technological Innovation and Expertise

At its core, PerkinElmer leverages cutting-edge technologies to enable breakthrough discoveries in science and healthcare. The company continuously evolves its product offerings through innovation in instrument design, software integration, and application-specific solutions. These innovations are a direct result of its commitment to deep market insight and technical expertise, ensuring that its customers benefit from the latest advances in scientific research.

Global Reach and Impact

With a presence in numerous countries worldwide, the company functions as a key enabler in global research efforts. By providing technologies that support both clinical and research applications, PerkinElmer contributes significantly to improving healthcare outcomes and advancing scientific understanding. Its global footprint allows it to serve a diverse array of industries, reinforcing its role as a vital partner in enhancing quality of life through scientific progress.

Commitment to Quality and Customer Partnership

PerkinElmer is dedicated to building strategic partnerships with its customers, offering tailored support and service solutions that meet the specific requirements of complex research and diagnostic projects. This commitment is reflected in its holistic approach to customer engagement, combining product excellence with expert consultancy and robust technical assistance.

Conclusion

In summary, PerkinElmer Inc. encapsulates a sophisticated blend of innovation, market insight, and operational excellence. It remains an influential entity in the scientific and healthcare sectors by consistently providing analytical instrumentation and solutions that empower users to achieve early and accurate results. The company’s ability to integrate advanced technology with practical applications makes it an indispensable partner for global research institutions and healthcare providers alike.

Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its participation in the 43rd annual J.P. Morgan Healthcare Conference scheduled for January 13, 2025, at 8:15 a.m. PT in San Francisco. President and CEO Prahlad Singh will present an update on the company's strategic priorities and overall direction. The presentation will be accessible through a live audio webcast, with a replay available on the Revvity Investor Relations website for a minimum of 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Revvity (NYSE: RVTY) announced an expanded collaboration with Genomics England to advance genomic initiatives across the UK. The partnership focuses on the Generation Study, a research program aiming to screen up to 100,000 newborns for 200 rare genetic conditions in England. Through its Omics laboratory in Manchester, Revvity will extract DNA from cord blood samples using the chemagic 360™ instrument. The collaboration aims to advance early detection of genetic conditions in newborns while also supporting the development of genomics talent across the UK region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference scheduled for December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL. President and CEO Prahlad Singh will present an update on the company and its strategic priorities. The presentation will be accessible through a live audio webcast on the company's website's Events section, with a replay available on the Revvity Investor Relations website for at least 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Scale Biosciences and Revvity's BioLegend (NYSE: RVTY) have launched the TotalSeq Phenocyte solution, a groundbreaking single-cell protein profiling technology. This innovation combines Scale Bio's Quantum Barcoding technology with BioLegend's TotalSeq antibody conjugates to enable more efficient identification and characterization of rare cell subtypes in immunology and oncology research.

The solution offers advantages over traditional methods like mass cytometry and flow cytometry by eliminating complex panel optimization and sophisticated instrumentation requirements, making it more accessible and scalable. It builds upon BioLegend's TotalSeq-A antibody panels and supports biomarker discovery without requiring dedicated instrumentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its upcoming Investor Day scheduled for November 21, 2024, at 9:00 a.m. PT. The company revealed strategic changes to its operating model, effective fiscal year 2025, including the integration of its Applied Genomics business into a new Life Sciences Solutions division.

The reorganization will result in two main reporting segments: Life Sciences (comprising Life Sciences Solutions and Software) and Diagnostics (including Immunodiagnostics and Reproductive Health). This restructuring aims to enhance operational efficiency, create synergies, and improve customer service delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Revvity reported strong Q3 2024 financial results with revenue reaching $684 million, representing 2% reported and organic growth. GAAP EPS was $0.77, while adjusted EPS from continuing operations reached $1.28. The company's Diagnostics segment showed 6% growth with $383 million revenue, while Life Sciences recorded $301 million, a 2% decrease. Operating margins improved, with GAAP operating profit margin at 14.3% and adjusted operating profit margin at 28.3%. The company raised its full-year 2024 adjusted EPS guidance to $4.83-$4.87 and announced a new $1 billion share repurchase program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Revvity (NYSE: RVTY) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on February 7, 2025, to shareholders of record as of the close of business on January 17, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
Rhea-AI Summary

Revvity, Inc. (NYSE: RVTY) has launched Revvity Transcribe AI, an innovative optical character recognition (OCR) service that converts handwritten text on test request forms into digital format. This solution aims to streamline workflows and reduce manual data entry tasks in clinical laboratories. Key features include:

  • 40% improvement in overall data entry workflow speed, including data validation
  • Especially valuable for newborn screening (NBS) laboratories
  • Compatible with Revvity's EVOYA™ platform for NBS software
  • Secure data processing with ISO27001 compliance

The service allows laboratory personnel to focus on other essential tasks by automating the manually intensive process of transcribing handwritten information. Revvity Transcribe AI will be introduced at the 2024 APHL Newborn Screening Symposium in Omaha, Nebraska.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary

Revvity, Inc. (NYSE: RVTY) has released its annual Impact Report, showcasing the company's sustainability, social, and governance initiatives. Key highlights include:

  • A 7% reduction in Scope 1 and 2 emissions in 2023
  • Implementation of a sustainability due diligence program for suppliers
  • 75% employee satisfaction with 85% participation in a survey
  • Maintained 40% female representation in leadership positions
  • Expanded gender pay gap analysis
  • Introduction of new corporate policies on ethical AI, sustainable procurement, and cyber risk management
  • Creation of Revvity Access STEM Scholarships

CEO Prahlad Singh emphasized the company's commitment to creating a healthier, cleaner, and more inclusive world through innovative solutions and sustainability initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Revvity, Inc. (NYSE: RVTY) has announced its plans to release third quarter 2024 financial results before the market opens on Monday, November 4, 2024. The company will host a conference call at 8:00 a.m. ET on the same day to discuss these results. Prahlad Singh, president and CEO, and Max Krakowiak, CFO, will lead the conference call. Investors can access a live audio webcast of the call through the Investors section of Revvity's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the market cap of PERKINELMER (PKI)?

The market cap of PERKINELMER (PKI) is approximately 14.5B.

What core markets does PerkinElmer Inc. serve?

PerkinElmer serves markets such as diagnostics, life sciences, food safety, and applied research, providing a wide range of scientific instrumentation and solutions.

How does PerkinElmer generate its revenue?

The company generates revenue through direct sales of advanced analytical instruments, licensing of proprietary technologies, and comprehensive service contracts.

What distinguishes PerkinElmer from its competitors?

PerkinElmer distinguishes itself through its deep market expertise, integrated solutions, and commitment to customer partnerships, offering tailored support alongside state-of-the-art technology.

How does PerkinElmer contribute to advancements in healthcare and research?

By providing cutting-edge diagnostic and analytical tools, PerkinElmer enables early detection and accurate research insights, which are essential for improving healthcare outcomes and advancing scientific discovery.

What is the significance of PerkinElmer's focus on innovation?

Innovation is central to PerkinElmer's strategy, driving the development of advanced instruments and software that meet evolving market needs and support breakthrough research initiatives.

In which regions does PerkinElmer operate?

PerkinElmer operates on a global scale, serving a diverse range of markets across multiple continents, which underscores its expansive reach and influence in the scientific and healthcare sectors.

How does PerkinElmer support its customer base?

The company emphasizes strategic partnerships, offering tailored technical support, consultancy, and post-sales services to ensure that customers maximize the value of their investments in analytical solutions.

What industry-specific expertise does PerkinElmer offer?

PerkinElmer leverages extensive expertise in diagnostic methodologies and analytical instrumentation, ensuring its solutions meet the complex requirements of both clinical and research environments.
PERKINELMER INC

NYSE:PKI

PKI Rankings

PKI Stock Data

14.46B
109.03M
0.27%
86.26%
2.79%
Diagnostics & Research
Healthcare
Link
United States
Waltham